

## **Biophytis to participate in several investors' events during the month of April**

Paris, France, April 4, 2019 - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel treatments for age-related diseases, today announced its participation to several investors' events in London and Paris over the month of April.

- The H.C. Wainwright Global Life Sciences Conference which will be held in London from the 7<sup>th</sup> to the 9<sup>th</sup> of April 2019.
- The 14<sup>th</sup> edition of the Small Cap Event which will be held in the Westin Hotel in Paris the 16<sup>th</sup> and 17<sup>th</sup> of April 2019.

### **About Biophytis**

Biophytis is a clinical-stage biotechnology company focused on the development of novel therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological stresses that lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy. Our second drug candidate, Macuneos (BIO201), is for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit [www.biophytis.com](http://www.biophytis.com).

### **Disclaimer**

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are not promises or guarantees and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of the risks and uncertainties that could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please consult the Risk Factors section of the Company's registration document and other regulatory filings filed with the French Autorité des Marchés Financiers (AMF), which are available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) and at [www.biophytis.com](http://www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

### **Biophytis Investor Relations Contact**

Daniel Schneiderman, CFO  
dan.schneiderman@biophytis.com  
Tel: +1 (857) 220-9720

**U.S. Media Contact**

*LifeSci Public Relations*  
Cherilyn Cecchini, M.D.  
ccecchini@lifescipublicrelations.com  
Tel: +1 (646) 876-5196

**Europe Media Contact**

*Citigate Dewe Rogerson*  
Antoine Denry  
antoine.denry@citigatedewerogerson.com  
Tel: +33 (0) 1 53 32 84 78

Source: Biophytis SA